What's new this week?
The ideal combination of news, articles, webinars and podcast's, all to keep you up-to-date with what's been happening in the drug development industry this week...
Trending news from the industry:
In this exclusive interview with Dr Christopher Haqq (Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics), we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted Amphiphile-Immunotherapy to enhance anti-tumour function and eradicate solid tumours. Read more.
In this interview, Dr Amber D. Van Laar explores the profound impact of her early exposure to neuro-oncology, the challenges faced as a physician-scientist, and the pursuit of innovative gene therapies. Dr Van Laar reflects on the power of mentorship, the significance of diverse perspectives in STEM, and the projects that have reshaped the understanding of neurodegenerative diseases. Read more.
Researchers have developed the world’s first animal model with A-to-G mtDNA edits achieved using engineered TALEDs. Read more.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development. Read more.
Limb bud progenitor cells efficiently generated new cartilage in osteoarthritis patients, which could lead to cartilage replacement therapy. Read more.
What to read:
Amidst the transformative era of artificial intelligence in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision and effectiveness in identifying drug targets. Download now.
See experiments showcasing the straightforward setup and clear results of assays for secreted IFN-γ, TNF-α, and granzyme B. Discover how to successfully separate cells with the desired activity from the rest of the population and recover them alive. Explore experiments on the co-encapsulation of natural killer cells and their target lymphoblasts, highlighting the versatility of DE50 droplets.
Immerse yourself in the future of immunotherapy research with Xdrop DE50 droplets. This eBook aims to provide compelling results that showcase why these droplets are the key to answering critical questions in the field.
Recommended by LinkedIn
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding. Learn how to enable high-throughput measurement of antibody binding activity. Download now.
Bought to you by Sartorius, this article highlights the features of advanced flow cytometry, such as assay miniaturization and automation capabilities, and demonstrates how it can dramatically increase throughput, whilst making it easier to obtain biologically relevant insights. Data may be created and stored in compliance with the requirements of 21 CFR Part 11. Download now.
Supported by BellBrook Labs, This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times. Download now.
What to watch:
Join this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts will outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have potential to expand future applications for gene therapy. Register now.
What to listen to:
We have a brand new podcast episode: High-throughput screening: rapid advancements in drug discovery. Tune in to discover the latest technological advancements in high throughput screening and more.
This conversation features Dr Luke Alderwick, Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL), and Dr Sachin Mahale, Research Leader in High Throughput Screening at Charles River Laboratories.
We'd like your feedback:
We value our community and the feedback you provide. Your insights help us improve and better serve your needs. That's why we're reaching out to YOU for your valuable input! Take just 10 minutes to complete our survey, and as a token of our appreciation, we'll donate US$5 to your choice of UNICEF or One Tree Planted.
Sign up for free!
Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.
Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.